Mannkind (MNKD)

Company Profile

MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut.

Company profile

Ticker

MNKD

Exchange

NASDAQ

Website

www.mannkindcorp.com

CEO

Michael Castagna

Incorporated

Delaware

Location

Connecticut

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Abbott Laboratories • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies ...

SEC CIK

0000899460

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

133607736

MNKD stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

8-K

Departure of Directors or Certain Officers

30 May 23

8-K/A

Mannkind Corporation Reports 2023 First Quarter Financial Results

9 May 23

Mannkind Corporation Reports 2023 First Quarter Financial Results

9 May 23

DEFA14A

Additional proxy soliciting materials

14 Apr 23

DEFA14A

Additional proxy soliciting materials

10 Apr 23

Lauren Sabella Joins Mannkind As Executive

27 Mar 23

8-K

Mannkind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results

23 Feb 23

Transcripts

View all

MNKD

Earnings call transcript

2023 Q1

9 May 23

MNKD

Earnings call transcript

2022 Q4

23 Feb 23

MNKD

Earnings call transcript

2022 Q3

8 Nov 22

MNKD

Earnings call transcript

2022 Q2

10 Aug 22

MNKD

Earnings call transcript

2022 Q1

6 May 22

MNKD

Earnings call transcript

2021 Q4

25 Feb 22

MNKD

Earnings call transcript

2021 Q3

10 Nov 21

MNKD

Earnings call transcript

2021 Q2

12 Aug 21

MNKD

Earnings call transcript

2021 Q1

13 May 21

MNKD

Earnings call transcript

2020 Q4

25 Feb 21

Latest ownership filings

View all

Michael Castagna

2 Jun 23

144

Notice of proposed sale of securities

Financial summary

Financial statements Chart MNKD financial data

Quarter (USD)	Mar 23	Dec 22	Sep 22	Jun 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	85.87 mm	85.87 mm	85.87 mm	85.87 mm	85.87 mm	85.87 mm
Cash burn (monthly)	(no burn)	(no burn)	3.27 mm	5.93 mm	(no burn)	5.11 mm
Cash used (since last report)	n/a	n/a	7.11 mm	12.93 mm	n/a	11.13 mm
Cash remaining	n/a	n/a	78.76 mm	72.94 mm	n/a	74.74 mm
Runway (months of cash)	n/a	n/a	24.1	12.3	n/a	14.6

Beta Read what these cash burn values mean

Financial data from Mannkind earnings reports.

Institutional ownership, Q1 2023

MNKD institutional ownership history Ownership history

56.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	184	193	-4.7%
Opened positions	23	40	-42.5%
Closed positions	32	19	+68.4%
Increased positions	58	64	-9.4%
Reduced positions	48	41	+17.1%

13F shares	Current	Prev Q	Change
Total value	544.02 bn	706.98 bn	-23.0%
Total shares	148.33 mm	149.19 mm	-0.6%
Total puts	369.70 k	868.90 k	-57.5%
Total calls	310.70 k	595.80 k	-47.9%
Total put/call ratio	1.2	1.5	-18.4%

Largest owners	Shares	Value	Change
BLK Blackrock	20.68 mm	$84.80 bn	-1.5%
STT State Street	17.89 mm	$73.34 bn	+3.6%
Vanguard	13.99 mm	$57.36 bn	+2.4%
CVI Investments	10.65 mm	$13.73 mm	0.0%
Avoro Capital Advisors	9.10 mm	$37.31 bn	0.0%
FMR	6.46 mm	$26.47 bn	-0.0%
D. E. Shaw & Co.	5.81 mm	$23.82 bn	+3.7%
Geode Capital Management	5.16 mm	$21.14 bn	+4.9%
Emerald Advisers	3.64 mm	$14.90 bn	-2.1%
Nuveen Asset Management	3.57 mm	$14.73 bn	+352.7%

Largest transactions	Shares	Bought/sold	Change
Millennium Management	0.00	-6.25 mm	EXIT
Nuveen Asset Management	3.57 mm	+2.78 mm	+352.7%
Schonfeld Strategic Advisors	847.01 k	-2.02 mm	-70.4%
Two Sigma Advisers	2.05 mm	+1.82 mm	+786.7%
Two Sigma Investments	3.07 mm	+1.58 mm	+106.6%
BAC Bank Of America	2.84 mm	+1.48 mm	+108.3%
Citadel Advisors	2.80 mm	-1.35 mm	-32.6%
Woodline Partners	1.83 mm	+1.11 mm	+154.5%
Renaissance Technologies	1.17 mm	-774.10 k	-39.8%
IVZ Invesco	123.41 k	-706.03 k	-85.1%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

MNKD insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Jun 23	Michael Castagna	Common Stock, $.01 Par Value	Sell	Dispose S	No	Yes	4.5302	10,000	45.30 k	2,516,735
26 May 23	Michael Castagna	Common Stock, $.01 Par Value	Sell	Dispose S	No	Yes	4.4978	75,000	337.34 k	2,526,735
25 May 23	David Thomson	Common Stock, $.01 Par Value	Grant	Acquire A	No	No	0	92,000	0.00	827,263
25 May 23	David Thomson	RSU Common Stock, $.01 Par Value	Grant	Acquire A	No	No	0	113,000	0.00	113,000
25 May 23	Mundkur Christine	RSU Common Stock	Grant	Acquire A	No	No	0	35,545	0.00	35,545
25 May 23	Michael Castagna	Common Stock, $.01 Par Value	Sell	Dispose S	No	Yes	4.5929	75,000	344.47 k	2,601,735
25 May 23	Michael Castagna	Common Stock, $.01 Par Value	Grant	Acquire A	No	No	0	345,000	0.00	2,676,735
25 May 23	Michael Castagna	RSU Common Stock, $.01 Par Value	Grant	Acquire A	No	No	0	422,000	0.00	422,000
25 May 23	Lauren M Sabella	Common Stock, $.01 Par Value	Grant	Acquire A	No	No	0	23,250	0.00	247,434
25 May 23	Lauren M Sabella	RSU Common Stock, $.01 Par Value	Grant	Acquire A	No	No	0	28,000	0.00	28,000